Attached files

file filename
EX-99.1 - EX-99.1 - AUXILIUM PHARMACEUTICALS INCa14-11869_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  May 5, 2014

 

Auxilium Pharmaceuticals, Inc.

(Exact Name of Registrant Specified in Charter)

 

Delaware

 

000-50855

 

23-3016883

(State or Other

Jurisdiction of

Incorporation)

 

(Commission File

Number)

 

(I.R.S. Employer

Identification No.)

 

640 Lee Road

 

 

Chesterbrook, PA

 

19087

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:   (484) 321-5900

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02              Results of Operations and Financial Condition.

 

On May 5, 2014, Auxilium Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2014. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

Item 7.01              Regulation FD Disclosure.

 

As previously announced, the Company will conduct a conference call today, Monday, May 5, 2014 at 8:30 a.m. ET to discuss results and highlights of the first quarter 2014.  The presentation slides to be used during the call will be available on the “Investors” section of the Company’s web site (http://www.auxilium.com) under the “Presentations” tab beginning at 8:30 a.m. ET on Monday, May 5, 2014.  A web cast of the conference call and the presentation slides will be available on the “Investors” section of the Company’s web site under the “Events” tab beginning at 8:30 a.m. ET on Monday, May 5, 2014, and will remain available for future review until August 5, 2014.  The information contained in, or that can be accessed through the Company’s web site, is not a part of this filing.

 

Item 9.01              Financial Statements and Exhibits

 

(d)           Exhibits.

 

The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be “filed”:

 

99.1        Press Release dated May 5, 2014 issued by Auxilium Pharmaceuticals, Inc.

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AUXILIUM PHARMACEUTICALS, INC.

 

 

 

 

Date: May 5, 2014

By:

/s/ James E. Fickenscher

 

 

 

 

 

 James E. Fickenscher

 

 

 Chief Financial Officer

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Description of Exhibit

 

 

 

99.1

 

Press Release dated May 5, 2014 issued by Auxilium Pharmaceuticals, Inc.

 

4